Cipla Limited has announced the launch of its Niveoli extra-fine
particle beclomethasone/formoterol fumarate MDI for the treatment of asthma and COPD in adults in India.
Cipla India Business Head Nikhil Chopra commented, “Cipla is pleased to offer yet another milestone in respiratory inhalation therapy. Niveoli marks a first in acknowledging and addressing the issue of drug delivery to the small airways. Cipla has a long history of blazing the trail in innovations in combination formulations and drug-device combinations in the respiratory therapy, and Niveoli is a painstaking result of these strengths. Be it the transparent dry powder inhaler, the static-free spacer with valve mechanism, the mask-spacer combination for children or our novel breath-actuated inhaler with dose counter called Synchrobreathe, the list is long.”
Chopra continued, “We see our market leadership as well as the range and depth of our R&D and manufacturing capabilities in this therapy as a privilege and a responsibility to do more for patients. In keeping with our purpose of ‘Caring for Life’, we are constantly studying OADs and working towards products that offer greater efficacy, ease of use and drug delivery to patients. I believe Niveoli represents a new paradigm in inhalation therapy.”
Read the Cipla press release.
